Article
Biochemistry & Molecular Biology
Nasser K. Yaghi, Mark R. Gilbert
Summary: This review examines the challenges faced by immunotherapies in treating glioblastoma, explores current treatment options, and proposes future directions for GBM immunotherapy.
Article
Oncology
Marie Blonski, Tiphaine Obara, Cyril Brzenczek, Celso Pouget, Celine Dillier, Mylene Meyer, Laura Lavigne, Natacha Forthoffer, Aurelie Broussois, Guillaume Gauchotte, Marie-Helene Baron, Fabien Rech, Sophie Mezieres, Yann Gaudeau, Antoine Verger, Guillaume Vogin, Rene Anxionnat, Jean-Marie Moureaux, Luc Taillandier
Summary: The study described a series of 20 patients treated with PCV followed by radiotherapy, showing significant neurotoxicity in long-term follow-up with memory and behavioral deterioration, leading to disability and inability to work in 65% of patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Aleksandra Napieralska, Aleksandra Krzywon, Agnieszka Mizia-Malarz, Joanna Sosna-Zielinska, Ewa Pawlowska, Malgorzata A. Krawczyk, Katarzyna Konat-Baska, Aneta Kaczorowska, Anna Dabrowska, Maciej Harat
Summary: A retrospective analysis of 82 pediatric patients treated for high-grade gliomas showed a 5-year overall survival rate of only 30%. Factors such as extent of resection, chemotherapy, and radiotherapy were found to positively influence survival. High-grade gliomas in children remain rare and data on long-term outcomes are limited.
Review
Oncology
Arnaud Lombard, Hugues Duffau
Summary: This study reviewed the current knowledge about sexual dysfunction in LGG patients. Despite a high incidence of 44% to 62%, this issue has been largely neglected in research. Therefore, there is a need to systematically assess the occurrence of SD in clinical routine in order to adjust treatment and improve patients' QoL.
Review
Immunology
Boyuan Huang, Xuesong Li, Yuntao Li, Jin Zhang, Zhitao Zong, Hongbo Zhang
Summary: Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor in the central nervous system. Immunotherapy has shown promising results in the treatment of GBM, but future developments will require an integrated approach with various treatment modalities and specific targeted therapies for the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Health Care Sciences & Services
Fabiana Gregucci, Alessia Surgo, Roberta Carbonara, Letizia Laera, Maria Paola Ciliberti, Maria Annunziata Gentile, Morena Caliandro, Nicola Sasso, Ilaria Bonaparte, Vincenzo Fanelli, Romina Tortora, Eleonora Paulicelli, Giammarco Surico, Giuseppe Lombardi, Francesco Signorelli, Alba Fiorentino
Summary: The study evaluated the safety and efficacy of re-irradiation with radiosurgery or fractionated stereotactic radiotherapy in association with chemotherapy for recurrent high-grade gliomas. The results demonstrated that this treatment approach is safe and feasible for patients with recurrent HGG.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Clinical Neurology
Shami Acharya, Jose Pedro Lavrador, Priya Pavninder Sekhon, Ravindran Visagan, Josephine Jung, Richard Gullan, Francesco Vergani, Ranjeev Bhangoo, Keyoumars Ashkan
Summary: The study observed that the management approach for patients with low-grade gliomas has evolved over the past decade, showing a shift towards more radical surgical procedures associated with improved survival rates, reduced need for postoperative adjuvant therapy, and better seizure control.
WORLD NEUROSURGERY
(2021)
Article
Multidisciplinary Sciences
Mahdie Mousavi, Fereshteh Koosha, Ali Neshastehriz
Summary: A novel nanocomplex, SPIO@AuNP-Cisplatin-Alginate (SACA), was synthesized and characterized. The combination of SACA and 6 MV X-ray significantly decreased the viability of U87MG cells and increased apoptosis, indicating that this nanocomplex effectively enhanced the radiosensitivity of cancer cells.
Review
Neurosciences
Asraa Faris Aldoghachi, Ahmed Faris Aldoghachi, Koen Breyne, King-Hwa Ling, Pike-See Cheah
Summary: Glioblastoma multiforme (GBM) is a common and deadly malignant astrocytoma, and despite advancements in treatment, recurrence and low survival rates remain challenges. Investigating new treatment alternatives is crucial to improve GBM treatment strategies.
Article
Oncology
Martin Klein, A. Josephine Drijver, Martin J. van den Bent, Jacolien C. Bromberg, Khe Hoang-Xuan, Martin J. B. Taphoorn, Jaap C. Reijneveld, Mohamed Ben Hassel, Elodie Vauleon, Danielle B. P. Eekers, Tzahala Tzuk-Shina, Anna Lucas, Salvador Villa Freixa, Vasilis Golfinopoulos, Thierry Gorlia, Andreas F. Hottinger, Roger Stupp, Brigitta G. Baumert
Summary: The study found no significant difference in memory functioning between high-risk low-grade glioma patients receiving radiotherapy and those receiving TMZ chemotherapy as primary treatment. Both treatment arms showed improvement in immediate recall and total number of words recalled in the first year, with delayed improvement in the radiotherapy group.
Article
Oncology
Zili Tang, Ivana Dokic, Maximilian Knoll, Federica Ciamarone, Christian Schwager, Carmen Klein, Gina Cebulla, Dirk C. Hoffmann, Julian Schlegel, Philipp Seidel, Christiane Rutenberg, Stephan Brons, Christel Herold-Mende, Wolfgang Wick, Juergen Debus, Dieter Lemke, Amir Abdollahi
Summary: This study reveals that invasive tumor cells in glioblastoma exhibit high radioresistance and are closely associated with patient prognosis. Transcriptome analysis identifies the gene expression profile of invasive cells and validates the involvement of key pathways. Inhibition of specific signaling pathways and the use of carbon ion therapy can enhance the sensitivity of invasive cells to radiation treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Antoine Seyve, Caroline Dehais, Olivier Chinot, Apolline Djelad, Elisabeth Cohen-Moyal, Charlotte Bronnimann, Carole Gourmelon, Evelyne Emery, Philippe Colin, Mathieu Boone, Elodie Vauleon, Olivier Langlois, Anna-Luisa Di Stefano, Romuald Seizeur, Francois Ghiringhelli, Anne D'Hombres, Loic Feuvret, Jacques Guyotat, Laurent Capelle, Catherine Carpentier, Louis Garnier, Jerome Honnorat, David Meyronet, Karima Mokhtari, Dominique Figarella-Branger, Francois Ducray
Summary: This study investigates the incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG). It suggests that pseudoprogression is not only frequent but also frequently misdiagnosed in IDHmt HGG patients. The study highlights the importance of considering pseudoprogression within the first 2 years after radiotherapy.
Article
Oncology
Grace S. Ahn, Kihwan Hwang, Tae Min Kim, Chul Kee Park, Jong Hee Chang, Tae-Young Jung, Jin Hee Kim, Do-Hyun Nam, Se-Hyuk Kim, Heon Yoo, Yong-Kil Hong, Eun-Young Kim, Dong-Eun Lee, Jungnam Joo, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Seok-Gu Kang, Jeong Hoon Kim, Chae-Yong Kim
Summary: The addition of concurrent and adjuvant temozolomide did not negatively impact health-related quality of life (HRQoL) and was associated with improved progression-free survival (PFS) for patients with anaplastic gliomas.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Nauman Malik, Benjamin Geraghty, Archya Dasgupta, Pejman Jabehdar Maralani, Michael Sandhu, Jay Detsky, Chia-Lin Tseng, Hany Soliman, Sten Myrehaug, Zain Husain, James Perry, Angus Lau, Arjun Sahgal, Gregory J. Czarnota
Summary: This study investigated the use of radiomics-based approach to distinguish between GBM PTR and LGG, showing that quantitative analysis of conventional MRI sequences can effectively differentiate between the two types of tumors.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Yu Wang, Jianmin Zhang, Wenbin Li, Taipeng Jiang, Songtao Qi, Zhongping Chen, Jingbo Kang, Lei Huo, Yunjie Wang, Qichuan Zhuge, Guodong Gao, Yuping Wu, Hua Feng, Gang Zhao, Xiaopeng Yang, Hui Zhao, Yirong Wang, Hui Yang, Dezhi Kang, Jun Su, Liang Li, Chuanlu Jiang, Gang Li, Yongming Qiu, Weimin Wang, Handong Wang, Zaihua Xu, Liwei Zhang, Renzhi Wang
Summary: The study revealed that only 15.8% of Chinese GBM patients received treatments compliant with the Stupp regimen, with main deviations related to temozolomide dosages and treatment durations. Patients who received Stupp regimen-compliant treatments had longer overall survival and progression-free survival.